Assessing Mind Medicine (MNMD) Valuation After A Strong Year Of Share Price Momentum [Yahoo! Finance]
Denium Therapeutics, Inc - Common Shares (MNMD)
Company Research
Source: Yahoo! Finance
See our latest analysis for Mind Medicine (MindMed). The recent 10.45% 1 month share price return and 13.95% 3 month share price return have come alongside a much stronger 77.37% 1 year total shareholder return, suggesting momentum has been building over a longer window. If MindMed's move has caught your attention, it could be a good moment to scan other healthcare names, starting with healthcare stocks With shares up sharply over the past year and trading at a large discount to a US$28.67 analyst target and intrinsic estimates, you now have to ask: is MindMed undervalued, or is the market already pricing in future growth? On a P/B basis, MindMed trades at 10.3x, while the last close was US$13.64. That puts it well above typical US pharma valuations. The P/B ratio compares a company's market value to its book value, which is essentially net assets on the balance sheet. For early stage biopharma names with little or no revenue, investors often lean on P/B because earnings ba
Show less
Read more
Impact Snapshot
Event Time:
MNMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNMD alerts
High impacting Denium Therapeutics, Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
MNMD
News
- Mind Medicine (MindMed) (NASDAQ:MNMD) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.MarketBeat
- Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026 [Yahoo! Finance]Yahoo! Finance
- Mind Medicine (MindMed) (NASDAQ:MNMD) is now covered by analysts at Jones Trading. They set a "buy" rating and a $61.00 price target on the stock.MarketBeat
- Psychedelics stocks could benefit from marijuana rescheduling: Jefferies [Seeking Alpha]Seeking Alpha
- Assessing Mind Medicine (MNMD)'s Valuation After Strong Multi-Year Share Price Gains [Yahoo! Finance]Yahoo! Finance
MNMD
Earnings
- 11/6/25 - Miss
MNMD
Sec Filings
- 1/12/26 - Form 8-K
- 12/29/25 - Form 4
- 12/29/25 - Form 4
- MNMD's page on the SEC website